Effects of tirzepatide, a novel dual GIP and GLP-1 receptor agonist, on lipid profiling in patients with type 2 diabetes

被引：0
|
作者：
Ruotolo, G. [1 ]
Roth, K. D. [1 ]
Milligan, P. L. [1 ]
Lin, Y. [1 ]
Wilson, J. M. [1 ]
Pirro, V [1 ]
Duffin, K. L. [1 ]
Haupt, A. [1 ]
机构：
[1] Eli Lilly & Co, Indianapolis, IN 46285 USA
来源：
EUROPEAN HEART JOURNAL | 2020年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：3056 / 3056
页数：1
相关论文
共 50 条
  • [31] Effects of Tirzepatide (TZP), a Novel Dual GIP and GLP-1 Receptor Agonist, on Biomarkers of Nonalcoholic Steatohepatitis (NASH) in Patients with T2D
    Hartman, Mark L.
    Sanyal, Arun
    Loomba, Rohit
    Wilson, Jonathan M.
    Bray, Ross
    Nikooienejad, Amir
    Duffin, Kevin L.
    Robins, Deborah A.
    Haupt, Axel
    [J]. DIABETES, 2019, 68
  • [32] Tirzepatide, a dual GIP/GLP-1 receptor agonist, interrupts metabolic adaptation to dietary restriction
    Coskun, T.
    Roell, W. C.
    O'Farrell, L. S.
    Beebe, E. C.
    Regmi, A.
    Emmerson, P. J.
    Milicevic, Z.
    Haupt, A.
    [J]. DIABETOLOGIA, 2020, 63 (SUPPL 1) : S58 - S59
  • [33] The Dual GIP and GLP-1 Receptor Agonist Tirzepatide Regulates Lipid and Carbohydrate Metabolism through GIPR in Adipose Tissue
    Samms, Ricardo Justin
    Christe, Michael E.
    Ruan, Xiaoping
    Moyers, Julie
    Regmi, Ajit
    Roell, William C.
    [J]. DIABETES, 2019, 68
  • [34] TIRZEPATIDE, A DUAL GIP AND GLP-1 RECEPTOR AGONIST, INCREASES INSULIN SENSITIVITY AND IMPROVES PANCREATIC BETA-CELL FUNCTION IN TYPE 2 DIABETES
    Pirro, V.
    Nikooienejad, A.
    Lin, Y.
    Willency, J.
    Wilson, J.
    Duffin, K.
    Robins, D.
    Milicevic, Z.
    Haupt, A.
    Thomas, M.
    [J]. DIABETES TECHNOLOGY & THERAPEUTICS, 2021, 23 : A165 - A165
  • [35] Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial
    Rosenstock, Julio
    Wysham, Carol
    Frias, Juan P.
    Kaneko, Shizuka
    Lee, Clare J.
    Lando, Laura Fernandez
    Mao, Huzhang
    Cui, Xuewei
    Karanikas, Chrisanthi A.
    Thieu, Vivian T.
    [J]. LANCET, 2021, 398 (10295): : 143 - 155
  • [36] EFFECTS OF TIRZEPATIDE, A NOVEL DUAL GIP AND GLP-1 RECEPTOR AGONIST, ON BIOMARKERS OF NON-ALCOHOLIC STEATOHEPATITIS (NASH) IN PROBABLE NASH SUBGROUPS OF PATIENTS WITH TYPE 2 DIABETES (T2D)
    Hartman, Mark
    Loomba, Rohit
    Sanyal, Arun J.
    Wilson, Jonathan M.
    Nikooienejad, Amir
    Bray, Ross
    Duffin, Kevin L.
    Robins, Deborah A.
    Haupt, Axel
    [J]. HEPATOLOGY, 2019, 70 : 1270A - 1271A
  • [37] Research Progress on the GIP/GLP-1 Receptor Coagonist Tirzepatide, a Rising Star in Type 2 Diabetes
    Ma, Zijun
    Jin, Kaiqin
    Yue, Mengmeng
    Chen, Xin
    Chen, Jun
    [J]. JOURNAL OF DIABETES RESEARCH, 2023, 2023
  • [38] Tirzepatide, a dual GIP/GLP-1 receptor agonist, is effective and safe when added to basal insulin for treatment of type 2 diabetes (SURPASS-5)
    Dahl, D.
    Onishi, Y.
    Norwood, P.
    Huh, R.
    Patel, H.
    Rodriguez, A.
    [J]. DIABETOLOGIA, 2021, 64 (SUPPL 1) : 13 - 14
  • [39] Risk of major adverse cardiovascular events and stroke associated with treatment with GLP-1 or the dual GIP/GLP-1 receptor agonist tirzepatide for type 2 diabetes: A systematic review and meta-analysis
    Stefanou, Maria-Ioanna
    Theodorou, Aikaterini
    Malhotra, Konark
    Aguiar de Sousa, Diana
    Katan, Mira
    Palaiodimou, Lina
    Katsanos, Aristeidis H.
    Koutroulou, Ioanna
    Lambadiari, Vaia
    Lemmens, Robin
    Giannopoulos, Sotirios
    Alexandrov, Andrei, V
    Siasos, Gerasimos
    Tsivgoulis, Georgios
    [J]. EUROPEAN STROKE JOURNAL, 2024, 9 (03) : 530 - 539
  • [40] Tirzepatide, a Dual GIP/GLP-1 Receptor Agonist, Is Effective and Safe When Added to Basal Insulin for Treatment of Type 2 Diabetes (SURPASS-5)
    Dahl, Dominik
    Onishi, Yukiko
    Norwood, Paul
    Huh, Ruth
    Patel, Hiren
    Rodriguez, Angel
    [J]. DIABETES, 2021, 70
12345